All In Biotech

Drug Trial Radar · NCT03256422

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

Randomized, Open-label and Multicentric Trial Evaluating the Non-inferiority of Antiretroviral Treatment Taken 4 Consecutive Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients With Controlled Viral Load Under Antiretroviral Therapy

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 640 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

640

Actual

Start

Sep 7, 2017

Primary completion

Aug 6, 2019

Study completion Mar 2, 2020

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba; Institut National de la Santé Et de la Recherche Médicale, France
First posted
Aug 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48, the non-inferiority of antiretroviral treatment taken 4 consecutive days a week versus continuous therapy, in HIV infected patients with controlled viral load for at least 12 months and stable antiretroviral treatment since 4 months.

Conditions

  • HIV Infections

Interventions

  • Treatment discontinuationDrug

    • Receiving tritherapy. Allowed treatment drugs are : 1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine 2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r 3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine 4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with therapeutic success at Week 48.Time frame: Week 48

Locations

63 sites in 1 country. Site status is shown where the registry gives one.

  • Centre hospitalier Victor Dupouy

    Argenteuil, France

  • Hôpital Henri Duffaut

    Avignon, France

  • CHRU Jean Minjoz

    Besançon, France

  • Avicenne

    Bobigny, France

  • Jean Verdier

    Bondy, France

  • Hôpital Saint-André

    Bordeaux, France

  • Hôpital Pellegrin

    Bordeaux, France

  • Hôpital Ambroise Paré

    Boulogne-Billancourt, France

  • Hôpital de la Côte de Nacre

    Caen, France

  • Hôpital Louis Pasteur

    Chartres, France

  • Antoine Beclère

    Clamart, France

  • Hôpital Gabriel Montpied

    Clermont-Ferrand, France

  • Centre hospitalier sud francilien

    Corbeil-Essonnes, France

  • CHI de Créteil

    Créteil, France

  • Hôpital Henri Mondor

    Créteil, France

  • Hôpital du Bocage

    Dijon, France

  • Hôpital Raymond Poincaré

    Garches, France

  • Hôpital Michallon

    Grenoble, France

  • CHD de la Roche Sur Yon

    La Roche-sur-Yon, France

  • Bicêtre

    Le Kremlin-Bicêtre, France

  • Centre Hospitalier du Mans

    Le Mans, France

  • Institut hospitalier franco-britannique

    Levallois-Perret, France

  • Hôpital Dupuytren

    Limoges, France

  • Hôpital de la Croix Rousse

    Lyon, France

  • Hôpital Edouard Herriot

    Lyon, France

  • Hôpital Sainte Marguerite

    Marseille, France

  • Hôpital Européen

    Marseille, France

  • Hôpital Gui de Chauliac

    Montpellier, France

  • Hôpital Emile Müller

    Mulhouse, France

  • Hôpital de l'Hôtel Dieu

    Nantes, France

  • Hôpital de l'Archet

    Nice, France

  • Hôpital Carémeau

    Nîmes, France

  • Hôpital de La Source

    Orléans, France

  • Hôpital Saint-Antoine

    Paris, France

  • Hôpital Necker

    Paris, France

  • Hôpital Bichat

    Paris, France

  • Hôpital de l'Hôtel Dieu

    Paris, France

  • Hôtel-Dieu

    Paris, France

  • Hôpital Saint-Louis

    Paris, France

  • Lariboisière

    Paris, France

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.